Introduction: Inflammatory bowel disease (IBD), comprised of Ulcerative Colitis (UC) and Crohn’s Disease (CD), is a chronic inflammatory condition of the gastrointestinal tract. Extraintestinal manifestations of these diseases can also cause life-threatening conditions, including deep vein thrombosis (DVT) and thromboembolic (TE) complications. IBD patients are at a two-fold increase of suffering from DVT and TE. The first step involves adequately treating the underlying IBD before they ever present with such complications. However, despite this, there are still no guidelines in place on how to manage anticoagulation in these patients in either the outpatient setting or while hospitalized. We looked to review what type of therapy IBD patients who ultimately suffered DVT or TE complication were on and how they were managed once hospitalized. Methods: We conducted a monocentric retrospective review of patients with a diagnosis of IBD who presented to our hospital with a DVT or some other TE between 2017- 2019. Demographic characteristics, comorbidities, hospital course and clinical outcomes were obtained. A chi-square test was used to compare non-parametric variables. Results: Forty-three patients meet inclusion criteria, 26 had Ulcerative Colitis (UC) and 17 had Crohn’s Disease (CD). 26.9% of patients with UC had a DVT previous to the study encounter compared to 5.9% of CD patients. The median (IQR) albumin and hemoglobin of the study cohort was 2.9 (2.5, 3.6) and 12 (10.1, 13.1), respectively. CD patients were more likely to be on a biologic (58.8%) compared to those with UC (11.5%, p< 0.01=5) while 38.5% of UC patients presented on a steroid compared to only 5.9% of CD patients with a DVT (p< 0.05). Three UC patients were started on steroids during their hospitalization. Furthermore, of the admitted patients, only 35.3% of patients had a gastroenterology consultation before discharge. All 33 (76.7%) patients that were started on anticoagulation during their hospital encounter were also discharged on them. Conclusion: Patient’s with IBD have an increased risk of DVT and TE events. Discrepancies between the use of biologics and steroids are seen between UC and CD. Patient with UC experience more recurrent thrombotic events compared to CD. The majority of these patients are initiated on anticoagulation only following a primary thrombotic event. There is also a tendency to not involve a gastroenterologist in the management of these complex and high-risk patients.